According to the reports from multiple clinical trials (9–12), the overall response rate (ORR) of PD-1 blockade with nivolumab or pembrolizumab ranged from 26% to 44%, thus indicating almost 50% of patients with severely progressed melanoma do not obtain complete or partial response, with roughly 24% reach a stable disease only. The gene discussed is PDCD1; the disease is melanoma.